Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Quest Diagnostics, Great Basin, Premaitha Health, and More

NEW YORK (360Dx) – Quest Diagnostics has completed the acquisition of the outreach services of the William W. Backus Hospital and the Hospital of Central Connecticut. The hospitals represent two of the five Hartford HealthCare hospitals. Testing performed by the two hospitals will transition to Quest's full-service laboratory in Marlborough, Massachusetts, and its rapid response labs in Connecticut. In 2016, Quest acquired the outreach laboratories of Hartford HealthCare's Clinical Laboratory Partners, a wholly owned subsidiary of HHC at the time.

In a document filed this week with the US Securities and Exchange Commission, Great Basin Scientific said investors have acquired $2.8 million in non-convertible senior secured notes, of which it expects to use $685,000 primarily to finance the search for a buyer to acquire some or all of its assets.

The firm said that it has retained FTI Capital Advisors as its financial advisor regarding the potential sale. Great Basin said that it could be forced to cease operations and seek bankruptcy protection if it is unable to consummate a sale.

In August, the firm said in a document filed with the SEC that it has received notice that it is in default of senior notes for $18.3 million.

Premaitha Health expects revenues for the first six months of its fiscal year 2017 to total £2.6 million ($3.5 million), an increase of about 75 percent over the £1.5 million in revenues in the first half of fiscal year 2016.

Test volumes for the first half of fiscal 2017, which ends September 30, are expected to exceed 22,000, double the number of the first half of fiscal 2016. Excluding Yourgene Bioscience, which the company acquired in March, test volumes were up 150 percent during the first half, totaling about 15,000 tests, compared to 6,000 tests during the first half of fiscal 2016, a number that excludes tests from Swiss customer Genoma, which entered bankruptcy in May.

Premaitha also said that Illumina’s patent lawsuit against the company went before the English High Court in July and that a judgment is expected by the end of this year.

MolecularMD is collaborating with Indica Labs to leverage MolecularMD’s diagnostic clinical testing solutions with Indica’s digital biomarker analysis services. The deal will enable the transition of preclinical research to the diagnostic setting and deployment of advanced imaging analysis workflows, the firms said. Financial and other terms of the deal were not disclosed.

Roche’s Ventana PD-L1 assay has been expanded for use in non-small cell lung cancer and metastatic urothelial carcinoma in countries that recognize CE marking and where Roche’s Tecentriq cancer immunotherapy is approved. The US Food and Drug Administration had previously approved the assay as a complementary diagnostic for assessing patients with NSCLC and mUC being considered for treatment with Tecentriq. It uses immune cell and tumor cell staining within the tumor microenvironment to evaluate patients with PD-L1 status.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.